All In Biotech

Drug Trial Radar · NCT05243797

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,594 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,594

Planned (sponsor's estimate)

Start

Sep 8, 2022

Primary completion

Apr 2028

Study completion Apr 2032

Sponsor

Lead sponsor
European Myeloma Network B.V.Research network
Sponsor type
Research network
Collaborators
Janssen Pharmaceutica
First posted
Feb 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Conditions

  • Multiple Myeloma

Interventions

  • TeclistamabDrug

    Teclistamab will be administered via a subcutaneous injection (SC)

  • LenalidomideDrug

    Lenalidomide will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: from randomization to the date of disease progression or death (approximately up to 8 years)
  2. Minimal Residual Disease (MRD)-negative Complete Response (CR)Time frame: at month 12

Locations

201 sites in 25 countries. Site status is shown where the registry gives one.

  • Banner University Medical Center Tucson, University of Arizona

    Phoenix, Arizona

  • UCLA Medical Center

    Los Angeles, California

  • University of California-Davis Cancer Center

    Sacramento, California

  • University of California, San Diego (UCSD) Medical Center

    San Diego, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Christiana Care

    Newark, Delaware

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • AdventHealth/Blood & Marrow Transplant Center, Florida Hospital Medical Group

    Orlando, Florida

  • Moffitt at Memorial Healthcare System

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • University of Illinois Medical Center at Chicago

    Chicago, Illinois

  • Greenebaum Cancer Center UM of MD

    Baltimore, Maryland

  • John Hopkins

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Mount Sinai Medical Center - 2

    New York, New York

  • Montefiore Medical Cente

    The Bronx, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University

    Durham, North Carolina

  • East Carolina University

    Greenville, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Seidman Cancer Center-University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Ohio State Medical Center, James Cancer Center

    Columbus, Ohio

  • Ohio Health Research Institute

    Columbus, Ohio

  • Lehigh Valley Health Network

    Allentown, Pennsylvania

  • Penn Medicine Lancaster General

    Lancaster, Pennsylvania

  • Abramson Cancer Center University of Pennsylvania Medical Center

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • Gibbs Cancer Center

    Spartanburg, South Carolina

  • Vanderbilt-Ingram Cancer Center (VICC)

    Nashville, Tennessee

  • Houston Methodist Hospital

    Houston, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

  • St Vincent HSHS (Green Bay Oncology)

    Green Bay, Wisconsin

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin

  • Froedtert Memorial Lutheran Hospital

    Milwaukee, Wisconsin

  • Hospital Italiano

    Buenos Aires, Argentina

Showing 40 of 201 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.